menu search

Skillz to report 2023 second quarter results on august 2 and host conference call and webcast

LAS VEGAS--(BUSINESS WIRE)--Skillz Inc. (NYSE: SKLZ) (“Skillz” or the “Company”), the leading mobile games platform bringing fair and fun comp...

July 19, 2023, 11:30 am

Dallasnews corporation announces schedule for second quarter 2023 financial results release and conference call

DALLAS, July 18, 2023 (GLOBE NEWSWIRE) — DallasNews Corporation (Nasdaq: DALN) said today that it will release second quarter 2023 financial results...

July 18, 2023, 8:40 pm

Royalty pharma to announce second quarter 2023 financial results on august 8, 2023

NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2023 financial r...

July 18, 2023, 8:15 pm

Ryanair's strength lies in its balance sheet and smart capital allocation

Ryanair, Europe's largest airline, has a strong balance sheet and minimal debt. This positions them to grow sustainably even in a situation where inte...

July 18, 2023, 7:30 pm

Penn entertainment (penn) completes barstool sportsbook migration

PENN Entertainment (PENN) announces the successful migration of Barstool Sportsbook & Casino to its Interactive Gaming Platform along with simultaneou...

July 17, 2023, 12:02 pm

Penn entertainment to report second quarter results and host conference call and webcast on august 9

WYOMISSING, Pa.--(BUSINESS WIRE)--PENN Entertainment, Inc. (Nasdaq: PENN) announced today that it will release its 2023 second quarter financial resul...

July 17, 2023, 10:00 am

Saudi exchange welcomes riyad capital as an equities market maker

Riyad Capital will simultaneously provide bid and ask quotes for Alrajhi Bank and Americana Restaurants International PLC Company equities … Read Fu...

July 16, 2023, 11:59 am

Vitesse energy announces second quarter 2023 earnings release date and conference call

CENTENNIAL, Colo.--(BUSINESS WIRE)--Vitesse Energy, Inc. (NYSE: VTS) (“Vitesse” or the “Company”) today announced that it plans to issue its s...

July 13, 2023, 4:06 pm

Light & wonder to report second quarter 2023 results on tuesday, august 8, 2023

LAS VEGAS--(BUSINESS WIRE)--Light & Wonder, Inc. (NASDAQ and ASX: LNW) (“Light & Wonder” or the “Company”), announced today it will release it...

July 12, 2023, 5:05 pm

Myr group inc. announces second-quarter 2023 earnings release and conference call schedule

THORNTON, Colo., July 12, 2023 (GLOBE NEWSWIRE) -- MYR Group Inc. (“MYR Group”) (NASDAQ: MYRG), a holding company of leading specialty contractors...

July 12, 2023, 4:00 pm

Imax to simultaneously release studio ghibli's how do you live?

IMAX theaters are set to witness the release of Studio Ghibli's latest film, How Do You Live?, on Jul 14 in Japan....

July 10, 2023, 11:45 am

Uso: improving risk appetite and backwardation point to strong total returns

The United States Oil ETF, LP should perform well due to the recovery in risk assets and the oil curve remaining in backwardation. Weakness in oil pri...

July 4, 2023, 6:00 am

Regeneron to report second quarter 2023 financial and operating results and host conference call and webcast on august 3, 2023

TARRYTOWN, N.Y., June 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quart...

June 29, 2023, 4:01 pm

Monday.com: healthy free cash flow and ~$950m cash with no long-term debt

monday.com Ltd. is a holistic software platform that resembles a young Atlassian Corporation or Salesforce, Inc. It offers a variety of products, incl...

June 26, 2023, 2:38 pm

Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...

June 24, 2023, 9:01 am

Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...

June 24, 2023, 9:01 am

Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...

June 24, 2023, 9:01 am

Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...

June 24, 2023, 9:01 am

Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...

June 24, 2023, 9:01 am

Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant chan...

June 24, 2023, 9:01 am


Search within

Pages Search Results: